News

The program is part of a collaboration between AstraZeneca and its worldwide biologics research and development unit MedImmune. It is intended at developing and commercializing durvalumab across various

Bial director of research & development department Patrício Soares-da-Silva said: "The study met its primary endpoint, which was the proportion of seizure-free patients for six consecutive months under

In the study, adult patients under 60 years of age with newly-diagnosed FLT3-mutated acute myeloid leukemia (AML) who received the investigational compound PKC412 (midostaurin) plus standard induction and

With this validation, the Radius application is complete and now under review by the EMA. Radius Health president and CEO Robert Ward said: "The MAA for abaloparatide-SC is

ADCT plans to initiate Phase I clinical trials in both NHL and ALL. ADCT-402 combines a humanized monoclonal antibody targeting CD19 with a pyrrolobenzodiazepine (PBD) warhead. In preclinical

Earlier this year, the company said it would delay its regulatory submission for basal insulin peglispro (BIL), the potential once-daily type 1 and type 2 diabetes treatment. The

The data supporting the application was generated in the four Phase 3 Astral clinical trials. Of the 1,035 patients treated with SOF/VEL for 12 weeks, 1,015 achieved the

The initial phase-one study will combine Amgen’s Blincyto (blinatumomab) with Merck’s Keytruda (pembrolizumab) to treat patients with diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma.

Acorda executive director of device and program management Sean Plunkett said: "CVT-427 represents an innovative approach to acute treatment of migraines. Applying Acorda’s proprietary ARCUS technology, we have